EWTX
HEALTHCAREEdgewise Therapeutics Inc
$36.99-1.02 (-2.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving EWTX Today?
No stock-specific AI insight has been generated for EWTX yet. However, EWTX was mentioned in the following AI insights:
52-Week Range
$12.15$39.96
$36.99
Fundamentals
Market Cap$3.8B
P/E Ratio—
EPS$-1.66
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume2.9M
Avg Volume (10D)—
Shares Outstanding107.5M
EWTX News
20 articles- Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC SaysYahoo Finance·May 8, 2026
- Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story?Yahoo Finance·May 7, 2026
- Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular IndicationsPR Newswire·May 7, 2026
- How This Biotech Scored 'A Clear Win' Where Bristol Myers FailedYahoo Finance·May 5, 2026
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesYahoo Finance·May 4, 2026
- Can Myqorzo Drive Growth for Cytokinetics Amid Competition?Yahoo Finance·Apr 17, 2026
- Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 PipelineYahoo Finance·Mar 30, 2026
- Why Edgewise Therapeutics Stock Topped the Market on TuesdayMotley Fool·Mar 17, 2026
- Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study ResultsYahoo Finance·Mar 16, 2026
- Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's NextYahoo Finance·Mar 16, 2026
- Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at ConferenceMarketbeat·Mar 16, 2026
- This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on SharesMotley Fool·Mar 15, 2026
- This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per ShareMotley Fool·Mar 15, 2026
- Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-UpYahoo Finance·Mar 10, 2026
- Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026Yahoo Finance·Mar 4, 2026
- Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific ConferenceYahoo Finance·Mar 3, 2026
- Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi‑Year Returns And Recent Share Price MomentumYahoo Finance·Feb 26, 2026
- Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular ProgramsYahoo Finance·Feb 26, 2026
- OrbiMed Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC FilingMotley Fool·Feb 20, 2026
- Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 DataMotley Fool·Feb 19, 2026
All 20 articles loaded
Price Data
Open$39.13
Previous Close$38.01
Day High$39.96
Day Low$37.00
52 Week High$39.96
52 Week Low$12.15
52-Week Range
$12.15$39.96
$36.99
Fundamentals
Market Cap$3.8B
P/E Ratio—
EPS$-1.66
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume2.9M
Avg Volume (10D)—
Shares Outstanding107.5M
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—